FILE PHOTO: Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Johnson & Johnson logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/Illustration
(Reuters) - Johnson & Johnson and the U.S. Department of Health and Human Services have expanded an agreement to support the next phase of COVID-19 vaccine candidate research and development, the company said on Saturday.
Under the agreement the company will commit approximately $604 million and the HHS Department's Biomedical Advanced Research and Development Authority will commit about $454 million to support the Phase 3 ENSEMBLE trial evaluating Janssen's investigational COVID-19 vaccine candidate as a single dose in up to 60,000 volunteers worldwide, the company said in a statement.
Limited time offer:
Just RM5 per month.
